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Open access under CC BA series of 19 huprines has been evaluated for their activity against cultured bloodstream forms of Try-
panosoma brucei and Plasmodium falciparum. Moreover, cytotoxicity against rat myoblast L6 cells was
assessed for selected huprines. All the tested huprines are moderately potent and selective trypanocidal
agents, exhibiting IC50 values against T. brucei in the submicromolar to low micromolar range and selec-
tivity indices for T. brucei over L6 cells of approximately 15, thus constituting interesting trypanocidal
lead compounds. Two of these huprines were also found to be active against a chloroquine-resistant
strain of P. falciparum, thus emerging as interesting trypanocidal–antiplasmodial dual acting compounds,
but they exhibited little selectivity for P. falciparum over L6 cells.
 2011 Elsevier Ltd. Open access under CC BY license.1. Introduction
Human African trypanosomiasis (HAT) and malaria are major
protozoan parasite diseases in developing countries, with their
main impact in the sub-Saharan Africa.1 Malaria is caused by Plas-
modium species and infects several hundred million people annu-
ally, causing 1–3 million deaths. HAT, which results from
infection with Trypanosoma brucei gambiense or T. brucei rhodes-
iense, currently kills 30,000 per year, although this can increase
10-fold during major epidemics.2,3
Despite the mortality and morbidity caused by these diseases,
conventional treatments are often inadequate.4–6 Of the drugs used
against HAT, suramin and pentamidine are polar molecules which
are highly charged at physiological pH, and cannot cross the blood–
brain barrier (BBB). They are thus ineffective against late stage
infection when, after an initial blood stream stage, parasites pene-
trate the central nervous system (CNS) giving rise to the classical
symptoms of HAT. The arsenical melarsoprol is used to treat late
stage disease, although it is extremely toxic, resulting in 5–10%
mortality due to reactive encephalopathy.2,4,7 Cerebral malaria also
causes severe disease episodes8 and brain penetration can also be
an issue for antimalarial drugs. However, the main limitation in
this case is the emergence of resistance, notably to chloroquine
(1, Fig. 1), which was the mainstay of antimalarial chemotherapy
for many decades.8–12+34 934035941.
z-Torrero).
Y license.Given the problems with current treatments for HAT and malar-
ia, there is a desperate need for new and better drugs.5,9,11,13,14With
malaria, alternative quinoline-based drugs bearing the 4-amino-7-
chloroquinoline core of chloroquine are being assessed as a means
of overcoming parasite resistance to the parent compound.9,15–19
Interestingly, several 4-amino-7-chloroquinolines,10,20 as well as
closely related 9-amino-6-chloroacridines such as quinacrine (2,
Fig. 1) and some derivatives thereof7,21–25 exhibit both antiplasmo-
dial and trypanocidal activity in vitro. Therefore, not only could
aminoquinoline-based drugs circumvent the problem of resistant
Plasmodium strains, but their dual antiplasmodial–trypanocidal
proﬁle could result in cost-effective treatments. Indeed, develop-
ment of single agents which can act against multiple disease-caus-
ing organisms in an analogous way to broad-spectrum antibiotics
would be an economic drug discovery approach of particular rele-
vance to developing countries, where malaria and trypanosomiasis
are endemic.22
Huprines constitute a class of 4-aminoquinoline-based com-
pounds which were developed a decade ago as inhibitors of the en-
zyme acetylcholinesterase and were postulated as a treatment for
Alzheimer’s disease.26–30 They have proved to be effective in the
inhibition of brain acetylcholinesterase in ex vivo studies,28 while
the so-called huprine X (4, Fig. 1), has been shown to ameliorate
memory and learning activities in middle aged mice,31 as well as
Alzheimer’s disease related brain neuropathology in a transgenic
mouse model.32 These results are clearly indicative that huprines
can cross the BBB and exert their actions within the CNS. Moreover,
in the above-mentioned behavioural studies, huprine X did not in-
duce adverse effects.
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Scheme 1. Synthesis of the novel huprines 8–11 and general structure of huprines
3–6 and 8–22.
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Figure 1. Structures of some antimalarial and trypanocidal 4-aminoquinoline-
based drugs: chloroquine, quinacrine and some huprines.
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test them as a new family of trypanocidal–antiplasmodial brain
permeable 4-aminoquinoline-based compounds. We recently re-
ported that huprines 3–6 exhibited IC50 values in the range
300 nM for in vitro inhibition of the culture forms of T. brucei
(strain 427).33 In the light of this moderately potent activity, we
have now assessed the trypanocidal and antiplasmodial activity
of a larger series of huprines. Herein, we report the synthesis of
four novel huprines which combine the structural features of the
previously tested huprines 3–6 (isopropyl and allyl groups at
position 9 and a halogen atom on the benzene ring), and the
evaluation of the in vitro activity of these and ﬁfteen previously
prepared huprines against cultured bloodstream forms of T. brucei
and Plasmodium falciparum (strain K1). Furthermore, in vitro
cytotoxic activity against rat skeletal myoblast L6 cells was
assessed for selected huprines.
2. Results and discussion
2.1. Chemistry
The novel huprines 8 and 9 were designed by combination of
structural features of the recently tested trypanocidal huprines
3–6, namely the chlorine atom at position 3 of huprines 3 and 4
and the isopropyl or allyl group at position 9 of huprines 5 and
6. Introduction of a ﬂuorine atom in a molecule often results in a
series of added values, including enhanced binding interactions,
metabolic stability or changes in physicochemical properties.34 In
particular, the incorporation of a ﬂuorine atom on the benzene ring
of huprines will increase lipophilicity and decrease the basicity and
hence the percent of protonation. This is likely to lead to better CNS
penetration. Thus, the two novel huprines 10 and 11were designed
by combination of the isopropyl or allyl group at position 9 of hup-
rines 5 and 6 with a ﬂuorine atom at position 1 (Scheme 1).
For the synthesis of the novel huprines, the enones 7 (R9 = iso-
propyl or allyl) were prepared as previously described, that is, by
nucleophilic addition of isopropylcerium chloride or allylmagne-
sium bromide to bicyclo[3.3.1]nonane-3,7-dione, followed by
mesylation of the resulting 3-isopropyl- or 3-allyl-2-oxa-1-ada-mantanol and silica gel-promoted fragmentation.27 Friedländer
condensation of these enones with commercially available 2-ami-
no-4-chlorobenzonitrile or with 2-amino-6-ﬂuorobenzonitrile in
the presence of AlCl3 as Lewis acid catalyst in reﬂuxing 1,2-dichlo-
roethane afforded moderate yields of the novel huprines 8–11,
after column chromatography puriﬁcation of the resulting crude
product through silica gel (Scheme 1).
For antiparasitic evaluation, the novel huprines were converted
into the corresponding hydrochlorides, which were fully character-
ized through their IR, 1H and 13C NMR spectra and elemental
analysis.
Huprines 3–6 and 12–22 were prepared as previously de-
scribed.26–29
The ease and cost of the synthesis of antiparasitic drugs repre-
sent a major issue in developing countries. These huprines have
been prepared by the above-mentioned four-step sequence from
the readily available bicyclo[3.3.1]nonane-3,7-dione, which in-
volves two rather expensive silica gel column chromatography
puriﬁcations. Very interestingly, a three-step synthetic sequence
for huprine derivatives has been reported, which avoids isolation
of the intermediate enones 7,35 and a recrystallization procedure
has been set up for the puriﬁcation of the ﬁnal huprine derivatives,
thus shortening the synthetic procedure, increasing its overall
yield, and avoiding the two chromatographic puriﬁcations. The im-
proved procedure would allow an easier, more efﬁcient, and cheap-
er synthesis of our huprine derivatives, which is very convenient if
they are intended to be used as antiparasitic drugs.
2.2. Trypanocidal activity and cytotoxicity
The in vitro activities of huprines 3–6 and 8–22 against cultured
bloodstream forms T. brucei, as well as the toxicity of the most po-
tent trypanocidal huprines to mammalian L6 cells, are shown in
Table 1.
All of the compounds displayed trypanocidal potency, with IC50
values within the range 0.6–6 lM. Given the narrow range of
potencies of the different huprines, no strong structure–activity
relationship trends can be found.
The presence of a chlorine atom at position 3 seems to promote
greater trypanocidal activity. 3-Chlorosubstituted huprines 3 and 4
displayed a similar potency against the cultured bloodstream
forms T. brucei used in this assay to that found against the strain
427 of this parasite, with IC50 values in the submicromolar range.33
9-Isopropyl- and 9-allyl-huprines 5 and 6were found to be one or-
der of magnitude less potent than previously described against the
Table 1
Trypanocidal and cytotoxic activities of huprinesa
Compd R1 R2 R3 R9 T. brucei IC50 (lM) T. brucei IC90 (lM) L6 cells IC50 (lM) SIb
3 H H Cl Me 0.61 ± 0.03 2.94 ± 0.20 7.80 ± 0.47 12.8
4 H H Cl Et 0.84 ± 0.06 1.76 ± 0.20 12.5 ± 0.40 14.9
5 H H H i-Pr 2.06 ± 0.44 4.76 ± 0.82 ndc
6 H H H Allyl 4.08 ± 0.45 8.52 ± 0.19 nd
8 H H Cl i-Pr 2.45 ± 0.37 4.34 ± 0.03 nd
9 H H Cl Allyl 0.76 ± 0.07 2.87 ± 0.18 12.4 ± 0.40 16.3
10 F H H i-Pr 2.60 ± 0.55 7.75 ± 0.23 nd
11 F H H Allyl 3.62 ± 0.54 8.73 ± 0.69 nd
12 H H H Et 1.29 ± 0.16 4.53 ± 0.16 15.6 ± 1.60 12.1
13 H H H n-Bu 0.70 ± 0.01 0.97 ± 0.06 6.75 ± 0.49 9.6
14 H H H t-Bu 0.88 ± 0.26 3.05 ± 0.03 11.6 ± 0.50 13.2
15 H H H Ph 1.65 ± 0.27 4.70 ± 0.27 3.51 ± 0.14 2.1
16 F H H Me 3.71 ± 0.56 15.8 ± 2.40 nd
17 H H Me Me 1.04 ± 0.05 3.31 ± 0.59 20.0 ± 0.50 19.2
18 Cl H H Et 1.36 ± 0.19 3.11 ± 0.29 21.3 ± 1.30 15.7
19 F H H Et 5.96 ± 0.58 9.50 ± 0.37 nd
20 Me H H Et 5.28 ± 1.11 8.86 ± 0.15 nd
21 H H F Et 4.16 ± 0.29 7.09 ± 0.29 nd
22 H Cl H Et 2.15 ± 0.27 5.02 ± 0.39 nd
a Huprines were tested for in vitro activity against bloodstream form T. brucei (pH 7.4) and rat myoblast L6 cells and the concentrations that inhibited growth by 50% (IC50)
and 90% (IC90, for trypanocidal activity) were calculated. Data are the mean of triplicate experiments ± SEM.
b SI: selectivity index is the ratio of cytotoxic to trypanocidal IC50 values.
c Not determined.
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5 and 6 led to the expected increased potency in the latter case, the
novel 3-chloro-substituted huprine 9 being ﬁvefold more potent
than 6, while huprine 8 was equipotent to the parent 5.
Introduction of a chlorine atom at other positions of the ben-
zene ring or introduction of other substituents onto the benzene
ring, particularly a ﬂuorine atom, was in general detrimental for
the trypanocidal activity. Thus, the novel 1-ﬂuoro-substituted hup-
rines 10 and 11 were equipotent with the parent huprines 5 and 6,
while 1-ﬂuoro- and 3-ﬂuoro-substituted huprines 19 and 21 were
5- and 3-fold less potent than their parent huprine 12, unsubstitut-
ed at the benzene ring. Also, when the activities of huprines with
ﬂuorine incorporations were compared with those in which chlo-
rine atoms had been added (cf. compound 4 with 21, and 18 with
19), it was apparent that ﬂuorine incorporation is associated with
decreased activity. Therefore, although incorporation of ﬂuorine
atoms into the benzene ring may act to increase lipophilicity of
the huprines, and potentially their CNS penetration, this is not re-
ﬂected in an increased potency against trypanosomes in vitro.
Regarding the substitution at position 9, replacement of the iso-
propyl or allyl groups of huprines 5 and 6, with either ethyl (12),
butyl (13), tert-butyl (14) or phenyl (15) side chains, led in each
case to a slight increase in trypanocidal activity. The most potent
huprines unsubstituted at the benzene ring turned out to be those
bearing a bulky butyl or tert-butyl group, which exhibited IC50 val-
ues in the submicromolar range.
The presence of a chlorine atom at position 3 is known to lead to
an increased acetylcholinesterase inhibitory activity, while the
contrary effect results from introduction of bulky substituents at
position 9.27,28 Indeed, 3-chloro-substituted huprines 3 and 4 are
the most potent acetylcholinesterase inhibitors within the whole
huprine family, while 9-butyl- and 9-tert-butyl-substituted hup-
rines 13 and 14 are the least potent acetylcholinesterase inhibitors
of the tested huprine series. Thus, the latter huprines seem to be
more adequate as trypanocidal agents since their use should be
associated with a lower incidence of cholinergically-mediated side
effects.
Cytotoxicity for the most potent trypanocidal huprines against
mammalian cells was evaluated in vitro, using cultured rat skeletal
myoblast L6 cells. Even though the tested compounds displayed a
modest toxicity toward the mammalian L6 cells with IC50 valuesranging from 3.51 to 21.3 lM (Table 1), with the sole exception
of compound 15 the tested huprines still possess selectivity indices
for T. brucei over L6 myoblasts (SI = IC50 against L6 cells/IC50
against T. brucei) between 10 and 20, rendering them interesting
trypanocidal lead compounds.
2.3. Antiplasmodial activity
The in vitro activities of huprines 3–6 and 8–22 against a chlo-
roquine-resistant strain of P. falciparum (strain K1) were
determined.
Only two of the nineteen huprine analogues, namely 13 and 15,
were found to have antiplasmodial activities (IC50) of less than
10 lM; their IC50 ± SD (n = 3) values, were 5.99 ± 1.64 and
7.12 ± 1.73 lM, respectively, as compared to 0.52 ± 0.11 lM for
the positive control, chloroquine diphosphate. Although these
activities are modest compared with that of chloroquine, it is note-
worthy that both of these compounds, especially 13, exhibited po-
tent activities against trypanosomes.
In this study a chloroquine-resistant strain of P. falciparum was
used but it would be of interest to evaluate 13 and 15 against a
chloroquine-sensitive strain of P. falciparum to determine whether
or not there is cross-resistance with chloroquine.
Huprine 13, which displays a SI = 9.6 for T. brucei over L6 cells, is
less selective toward P. falciparum (SI = 1.12), whereas huprine 15,
which exhibits a poor SI for T. brucei over L6 cells (SI = 2.1), is more
toxic to L6 cells than to P. falciparum (SI = 0.49).
Thus, in spite of the interesting dual trypanocidal–antiplasmo-
dial proﬁle of huprines 13 and 15, their therapeutic potential is
limited by low selectivity for P. falciparum over L6 cells. The data
also suggest that the antitrypanosomal and antiplasmodial activi-
ties of these compounds do not parallel each other, suggesting that
their mode(s) of action against the two parasite species may be
different.
3. Conclusions
Huprines have been found to display a moderately potent activ-
ity against cultured bloodstream forms T. brucei, particularly those
bearing a chlorine atom at position 3 or a bulky butyl or tert-butyl
substituent at position 9. Of these substitution patterns, the latter
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leads to a decreased acetylcholinesterase inhibitory activity, and
hence, it is likely to lead to a lower incidence of cholinergic side ef-
fects. Contrary to our expectations, huprines are in general not ac-
tive against P. falciparum, despite bearing the 4-aminoquinoline or
even the 4-amino-7-chloroquinoline core of the antimalarial drug
chloroquine. Only the 9-butyl- and 9-phenyl-substituted huprines
13 and 15 were found to be active against the chloroquine-resis-
tant strain K1 of P. falciparum. The most potent trypanocidal hup-
rines display selectivity indices for T. brucei over rat skeletal
myoblast L6 cells of approximately 15, thus constituting interest-
ing trypanocidal lead compounds. However, their less favorable
selectivity for P. falciparum over L6 cells, currently limits their po-
tential as antiplasmodial agents, and hence as dual acting trypan-
ocidal–antiplasmodial agents. Downstream development of
huprines as antiparasitic compounds would be greatly enhanced
by knowledge of their mechanism(s) of action and identiﬁcation
of their targets. In trypanosomes and Plasmodium, these are cur-
rently unknown, and on the basis of our data, may even be distinct.
This information could be used to guide the modiﬁcations within
this structural family that are needed to improve the antiplasmo-
dial action and/or reduce cytotoxicity so that a convenient thera-
peutic window can also be achieved.
4. Experimental
4.1. Chemistry
4.1.1. General
Melting points were determined in open capillary tubes with a
MFB 595010 M Gallenkamp melting point apparatus. 500 MHz 1H
NMR spectra and 75.4 MHz 13C NMR spectra were recorded in
CD3OD on Varian Inova 500 or Brucker DMX500 and Varian Gemini
300 spectrometers, respectively. The chemical shifts are reported
in ppm (d scale) relative to internal TMS, and coupling constants
are reported in Hertz (Hz). Assignments given for the NMR spectra
of the new compounds have been carried out by comparison with
the NMR data of tacrine (9-amino-1,2,3,4-tetrahydroacridine) and
6-chlorotacrine, as model compounds, which in turn, were as-
signed on the basis of DEPT, COSY 1H/1H (standard procedures),
and COSY 1H/13C (gHMQC, gHSQC or gHMBC sequences) experi-
ments. The syn (anti) notation of the protons at position 13 of hup-
rines means that the corresponding proton at position 13 is on the
same (different) side of the quinoline moiety with respect to the
cyclohexene ring. IR spectra were run on a FT/IR Perkin–Elmer
model 1600 spectrophotometer. Absorption values are expressed
as wave-numbers (cm1); only signiﬁcant absorption bands are gi-
ven. Column chromatography was performed on Silica Gel 60 AC.C
(35–70 mesh, SDS, ref 2000027). Thin-layer chromatography (TLC)
was performed with aluminum-backed sheets with Silica Gel 60
F254 (Merck, ref 1.05554), and spots were visualized with UV light
and 1% aqueous solution of KMnO4. Analytical grade solvents were
used for crystallization, while pure for synthesis solvents were
used in the reactions, extractions and column chromatography.
For characterization purposes, the new huprines 8–11 were trans-
formed into the corresponding hydrochlorides and recrystallized.
Worthy of note, as previously reported for some structurally re-
lated compounds,36 the new huprines have the ability to retain
molecules of water and of solvents of crystallization, which cannot
be removed after drying the analytical samples at 80 C/1 Torr for
2 days. Thus, the elemental analyses of these compounds showed
the presence of variable amounts of water and in some cases of
EtOAc, used in the crystallization. NMR spectra of all of the new
compounds were performed at the Serveis Cientiﬁcotècnics of
the University of Barcelona, while elemental analyses were carriedout at the Mycroanalysis Service of the IIQAB (CSIC, Barcelona,
Spain), respectively.
4.1.2. 12-Amino-3-chloro-6,7,10,11-tetrahydro-9-isopropyl-7,
11-methanocycloocta[b]quinoline hydrochloride, 8HCl
To a suspension of anhydrous AlCl3 (570 mg, 4.27 mmol) and
freshly sublimed 2-amino-4-chlorobenzonitrile (618 mg,
4.05 mmol) in 1,2-dichloroethane (6 mL) was added dropwise a
solution of enone 7 (R9 = i-Pr) (440 mg, 2.50 mmol) in 1,2-dichloro-
ethane (27 mL). The reaction mixture was stirred under reﬂux for
14 h, allowed to cool to room temperature, diluted with water
(35 mL) and THF (35 mL), made basic by addition of 5 N NaOH
(20 mL), and stirred at room temperature for 30 min. The organic
solvents were removed under reduced pressure, and the residue
was ﬁltered. The brown solid residue (698 mg) was subjected to
column chromatography [silica gel (50 g), CH2Cl2/MeOH/25% aque-
ous NH4OHmixtures as eluent]. On elution with CH2Cl2/MeOH/25%
aqueous NH4OH 98:2:0.5, huprine 8 (335 mg, 48% yield) was ob-
tained as a beige solid.
A solution of huprine 8 (335 mg, 1.07 mmol) in CH2Cl2 (15 mL)
was ﬁltered through a polytetraﬂuoroethylene (PTFE) 0.45 lm ﬁl-
ter, treated with 1.81 N methanolic solution of HCl (1.24 mL,
2.24 mmol), and the resulting solution was evaporated under re-
duced pressure. After recrystallization of the resulting solid residue
from AcOEt/MeOH 8:1 (9 mL), 8HCl (274 mg) was obtained as a
beige solid, mp 218–219 C (AcOEt/MeOH 8:1). IR (KBr) m
3500–2500 (max at 3476, 3322, 3172, 2956, 2926, 2892, 2821,
C–H, N–H, and N+–H st), 1644, 1609, 1576, and 1557 (ar–C–C
and ar–C–N st) cm1; 1H NMR (500 MHz, CD3OD) d 0.80 (d,
J = 7.0 Hz, 3H) and 0.84 (d, J = 7.0 Hz, 3H) [9-CH(CH3)2], 1.92 (dm,
J = 12.0 Hz, 1H, 13-Hsyn), 1.97–2.06 [complex signal, 2H, 13-Hanti
and 9-CH(CH3)2], 2.09 (d, J = 17.0 Hz, 1H, 10-Hendo), 2.45 (dd,
J = 17.0 Hz, J0 = 5.0 Hz, 1H, 10-Hexo), 2.70 (m, 1H, 7-H), 2.82 (ddd,
J = 17.5 Hz, J0 = J00 = 2.0 Hz, 1H, 6-Hendo), 3.05 (dd, J = 17.5 Hz,
J0 = 5.5 Hz, 1H, 6-Hexo), 3.34 (m, 1H, 11-H), 4.86 (s, NH2 and NH+),
5.52 (dm, J = 5.0 Hz, 1H, 8-H), 7.30 (dd, J = 8.5 Hz, J0 = 2.0 Hz, 1H,
2-H), 7.66 (d, J = 2.0 Hz, 1H, 4-H), 8.06 (d, J = 8.5 Hz, 1H, 1-H); 13C
NMR (75.4 MHz, CD3OD) d 21.4 (CH3) and 21.9 (CH3) [9-CH(CH3)2],
28.2 (CH, C11), 29.2 (CH, C7), 30.4 (CH2, C13), 32.3 (CH2, C10), 35.9
[CH, 9-CH(CH3)2], 39.5 (CH2, C6), 115.5 (C) and 116.6 (C) (C11a and
C12a), 122.9 (CH, C4), 124.6 (CH), 124.9 (CH), and 125.4 (CH) (C1,
C2, and C8), 136.6 (C, C4a), 143.9 (C) and 145.9 (C) (C3 and C9),
151.4 (C) and 157.8 (C) (C5a and C12). Anal. Calcd for
C19H21ClN2HCl1/3H2O (355.25): C, 64.24; H, 6.43; N, 7.89; Cl,
19.96. Found: C, 64.09; H, 6.45; N, 7.64; Cl, 19.70.
4.1.3. 9-Allyl-12-amino-3-chloro-6,7,10,11-tetrahydro-7,11-
methanocycloocta[b]quinoline hydrochloride, 9HCl
It was prepared as described for 8. Starting from freshly
sublimed 2-amino-4-chlorobenzonitrile (618 mg, 4.05 mmol) in
1,2-dichloroethane (10 mL) and enone 7 (R9 = allyl) (475 mg,
2.70 mmol) in 1,2-dichloroethane (20 mL), and heating the reac-
tion mixture under reﬂux for 18 h, a crude product (958 mg) was
obtained and subjected to column chromatography [silica gel
(75 g), CH2Cl2/MeOH/25% aqueous NH4OH mixtures as eluent].
On elution with CH2Cl2/MeOH/25% aqueous NH4OH 95:5:0.5, hup-
rine 9 (163 mg, 19% yield) was obtained as a beige solid.
A solution of huprine 9 (163 mg, 0.50 mmol) in MeOH (5 mL)
was treated with 1.81 N methanolic HCl (0.95 mL, 1.72 mmol)
and the resulting solution was evaporated under reduced pressure.
After recrystallization of the resulting solid residue from AcOEt/
MeOH 4:1 (12 mL), 9HCl (171 mg) was obtained as a light brown
solid, mp >300 C (dec.) (AcOEt/MeOH 4:1). IR (KBr) m 3500–2500
(max at 3338, 3174, 3080, 2926, 2903, 2821, 2681, C–H, N–H,
and N+–H st), 1654, 1634, 1603, and 1586 (ar–C–C and ar–C–N
st) cm1; 1H NMR (500 MHz, CD3OD) d 1.97 (dm, J = 12.5 Hz, 1H,
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1H, 13-Hanti), 2.50 (br dd, J = 17.5 Hz, J0 = 5.5 Hz, 1H, 10-Hexo), 2.61
(d, J = 7.0 Hz, 2H, 9-CH2–CH@CH2), 2.83 (m, 1H, 7-H), 2.87 (dm,
J = 18.0 Hz, 1H, 6-Hendo), 3.22 (dd, J = 18.0 Hz, J0 = 5.5 Hz, 1H, 6-
Hexo), 3.39 (m, 1H, 11-H), 4.86 (s, NH2 and NH+), 4.84 (m, 1H)
and 4.89 (m, 1H) (9-CH2–CH@CH2), 5.63 (dm, J  4.0 Hz, 1H, 8-
H), superimposed in part 5.64 (ddt, J = 17.0 Hz, J0 = 10.0 Hz,
J00 = 7.0 Hz, 1H, 9-CH2–CH@CH2), 7.58 (dd, J = 9.0 Hz, J0 = 2.0 Hz,
1H, 2-H), 7.75 (d, J  2.0 Hz, 1H, 4-H), 8.34 (d, J = 9.0 Hz, 1H, 1-
H); 13C NMR (75.4 MHz, CD3OD) d 27.6 (CH, C11), 28.2 (CH, C7),
29.3 (CH2, C13), 34.2 (CH2, C10), 36.1 (CH2, C6), 42.5 (CH2, 9-
CH2–CH@CH2), 115.3 (C) and 115.4 (C) (C11a and C12a), 116.4
(CH2, 9-CH2–CH@CH2), 119.5 (CH, C4), 125.8 (CH, C8), 126.2 (CH,
C1), 127.5 (CH, C2), 137.1 (CH, 9-CH2–CH@CH2), 137.2 (C, C9),
139.9 (C, C4a), 140.1 (C, C3), 153.2 (C) and 156.2 (C) (C5a and
C12). Anal. Calcd for C19H19ClN2HClH2O0.2EtOAc (382.92): C,
62.11; H, 6.21; N, 7.32; Cl, 18.52. Found: C, 62.25; H, 5.92; N,
7.31; Cl, 18.18.
4.1.4. 12-Amino-1-ﬂuoro-6,7,10,11-tetrahydro-9-isopropyl-7,
11-methanocycloocta[b]quinoline hydrochloride, 10HCl
It was prepared as described for 8. Starting from 2-amino-6-
ﬂuorobenzonitrile (318 mg, 2.31 mmol) in 1,2-dichloroethane
(25 mL) and enone 7 (R9 = i-Pr) (272 mg, 1.53 mmol) in 1,2-dichlo-
roethane (15 mL), a crude product (383 mg) was obtained and sub-
jected to column chromatography [silica gel (19 g), hexane/AcOEt/
25% aqueous NH4OH mixtures as eluent]. On elution with hexane/
AcOEt/25% aqueous NH4OH 98:2:0.1, huprine 10 (220 mg, 42%
yield) was obtained as a beige solid.
A solution of huprine 10 (220 mg, 0.74 mmol) in CH2Cl2 (15 mL)
was ﬁltered through a PTFE 0.45 lm ﬁlter, treated with 1.81 N
methanolic solution of HCl (1.24 mL, 2.24 mmol), and the resulting
solution was evaporated under reduced pressure. After recrystalli-
zation of the resulting solid residue from AcOEt/MeOH 30:1
(9.3 mL), 10HCl (138 mg) was obtained as a beige solid, mp
>300 C (dec.) (AcOEt/MeOH 30:1). IR (KBr) m 3500–2500 (max at
3494, 3370, 3312, 3201, 3158, 3024, 2958, 2929, 2891, 2833,
2750, 2669, C–H, N–H, and N+–H st), 1640, 1595, and 1548 (ar–
C–C and ar–C–N st) cm1; 1H NMR (500 MHz, CD3OD) d 0.87 (d,
J = 7.0 Hz, 3H) and 0.89 (d, J = 7.0 Hz, 3 H) [9-CH(CH3)2], 1.97
(dm, J = 12.5 Hz, 1H, 13-Hsyn), 2.02–2.12 [complex signal, 2H, 13-
Hanti and 9-CH(CH3)2], superimposed in part 2.08 (br d,
J = 17.5 Hz, 1H, 10-Hendo), 2.52 (br dd, J = 17.5 Hz, J0 = 5.0 Hz, 1H,
10-Hexo), 2.80 (m, 1H, 7-H), 2.86 (dm, J  18.0 Hz, 1H, 6-Hendo),
3.21 (dd, J = 18.0 Hz, J0 = 5.5 Hz, 1H, 6-Hexo), 3.41 (m, 1H, 11-H),
4.85 (s, NH2 and NH+), 5.58 (dm, J = 5.0 Hz, 1H, 8-H), 7.34 (ddd,
J = 13.5 Hz, J0 = 8.0 Hz, J00 = 1.0 Hz, 1H, 2-H), 7.56 (br d, J = 8.5 Hz,
1H, 4-H), 7.82 (dddm, J  J0  8.5 Hz, J00 = 5.5 Hz, 1H, 3-H); 13C
NMR (75.4 MHz, CD3OD) d 21.4 (CH3) and 21.9 (CH3) [9-CH(CH3)2],
27.2 (CH, C11), 27.9 (CH, C7), 29.6 (CH2, C13), 31.7 (CH2, C10), 35.9
[CH, 9-CH(CH3)2], 36.1 (CH2, C6), 107.2 (C, d, J  11.5 Hz, C12a),
112.2 (CH, d, J = 23.3 Hz, C2), 115.7 (C, C11a), 116.3 (CH, C4),
122.2 (CH, C8), 134.9 (CH, d, J  11.5 Hz, C3), 140.6 (C, C4a),
144.5 (C, C9), 152.9 (C) and 155.3 (C) (C5a and C12), 161.1 (C, d,
J = 253 Hz, C1). Anal. Calcd for C19H21FN2HCl3/4H2O (346.36): C,
65.89; H, 6.84; N, 8.09; Cl, 10.24. Found: C, 65.55; H, 6.62; N,
7.99; Cl, 10.21.
4.1.5. 9-Allyl-12-amino-1-ﬂuoro-6,7,10,11-tetrahydro-7,
11-methanocycloocta[b]quinoline hydrochloride, 11HCl
It was prepared as described for 8. Starting from freshly sub-
limed 2-amino-6-ﬂuorobenzonitrile (918 mg, 6.75 mmol) in 1,2-
dichloroethane (8 mL) and enone 7 (R9 = allyl) (800 mg,
4.50 mmol) in 1,2-dichloroethane (40 mL), and heating the reac-
tion mixture under reﬂux for 16 h, a crude product (1.75 g) was ob-
tained and subjected to column chromatography [silica gel (62 g),CH2Cl2/MeOH/25% aqueous NH4OH mixtures as eluent]. On elution
with CH2Cl2/MeOH/25% aqueous NH4OH 99:1:0.05, huprine 11
(762 mg, 58% yield) was obtained as a beige solid.
A solution of huprine 11 (762 mg, 2.59 mmol) in MeOH (6 mL)
was treated with 1.81 N methanolic HCl (4.3 mL, 7.78 mmol) and
the resulting solution was evaporated under reduced pressure.
After recrystallization of the resulting solid residue from AcOEt/
MeOH 15:2 (34 mL), 11HCl was obtained as a light brown solid
(570 mg), mp >300 C (dec.) (AcOEt/MeOH 15:2). IR (KBr) m
3600–2400 (max at 3394, 3314, 3201, 3166, 3071, 3020, 2926,
2902, 2829, 2774, 2669, 2604, C–H, N–H, and N+–H st), 1640,
1593, and 1548 (ar–C–C and ar–C–N st) cm1; 1H NMR
(500 MHz, CD3OD) d 1.98 (dm, J = 12.5 Hz, 1H, 13-Hsyn), 2.05 (br
d, J  17.5 Hz, 1H, 10-Hendo), 2.10 (dm, J = 12.5 Hz, 1H, 13-Hanti),
2.51 (ddm, J = 17.5 Hz, J0 = 5.5 Hz, 1H, 10-Hexo), 2.63 (d, J  7.0 Hz,
2H, 9-CH2–CH@CH2), 2.83 (m, 1H, 7-H), 2.88 (ddd, J = 18.0 Hz,
J0 = J00 = 2.0 Hz, 1H, 6-Hendo), 3.22 (dd, J = 18.0 Hz, J0 = 5.5 Hz, 1H, 6-
Hexo), 3.40 (m, 1H, 11-H), 4.86 (s, NH2 and NH+), 4.88–4.91 (com-
plex signal, 2H, 9-CH2–CH@CH2), 5.63 (dm, J = 7.0 Hz, 1H, 8-H),
superimposed in part 5.65 (ddt, J = 17.0 Hz, J0 = 10.0 Hz,
J00 = 7.0 Hz, 1H, 9-CH2–CH@CH2), 7.34 (ddd, J = 14.0 Hz, J0 = 8.5 Hz,
J00 = 1.0 Hz, 1H, 2-H), 7.57 (ddd, J = 8.5 Hz, J0 = J00 = 1.0 Hz, 1H, 4-H),
7.83 (ddd, J = J0 = 8.5 Hz, J00 = 6.0 Hz, 1H, 3-H); 13C NMR (75.4 MHz,
CD3OD) d 27.2 (CH, C11), 28.1 (CH, C7), 29.3 (CH2, C13), 34.0
(CH2, C10), 35.9 (CH2, C6), 42.5 (CH2, 9-CH2–CH@CH2), 107.4 (C,
d, J = 12.1 Hz, C12a), 112.2 (CH, d, J = 23.0 Hz, C2), 115.8 (C,
C11a), 116.3 (CH, C4), 116.4 (CH2, 9-CH2–CH@CH2), 125.7 (CH,
C8), 135.0 (CH, d, J = 11.5 Hz, C3), 137.2 (CH, 9-CH2–CH@CH2),
137.3 (C, C9), 140.7 (C, C4a), 152.9 (C) and 155.4 (C) (C5a and
C12), 161.2 (C, d, J = 253 Hz, C1). Anal. Calcd for C19H19FN2HCl
(330.83): C, 68.98; H, 6.09; N, 8.47; Cl, 10.72. Found: C, 68.65; H,
6.20; N, 8.35; Cl, 11.14.
4.2. T. brucei culturing and drug test
Bloodstream forms T. brucei (strain 427) were cultured at 37 C
in modiﬁed Iscove’s medium.37 Trypanocidal activity was assessed
by growing parasites for 48 h in the presence of various drug con-
centrations and determining the levels which inhibited growth by
50% (IC50) and 90% (IC90). In the case of untreated cultures, cell
densities increased from 0.25  105 to 1  106 over this period. Cell
densities at each drug concentration were determined using a
hemocytometer and drug sensitivity was expressed as a percent-
age of growth of control cells.
4.3. P. falciparum culturing and drug test
Malaria parasites were maintained in human A+ erythrocytes
suspended in RPMI 1640 medium supplemented with A+ serum
and D-glucose according to previously published methods.38,39 Cul-
tures containing predominantly early ring stages were used for
testing. Compounds were dissolved in DMSO and further diluted
with RPMI 1640 medium (the ﬁnal DMSO concentration did not
exceed 0.5% which did not affect parasite growth). Twofold serial
dilutions were made in 96-well microtitre plates in duplicate and
infected erythrocytes were added to give a ﬁnal volume of
100 lL with haematocrit 2.5% and 1% parasitaemia. Chloroquine
diphosphate was used as a positive control and uninfected and in-
fected erythrocytes without compounds were included in each
test. Plates were placed into a modular incubator gassed with
nitrogen 93%, oxygen 3%, carbon dioxide 4% and incubated at
37 C for 48 h. Parasite growth was assessed by measuring lactate
dehydrogenase activity.40 The reagent used contained the follow-
ing in each mL: acetylpyridine adenine dinucleotide (APAD),
0.74 mg; lithium lactate, 19.2 mg; diaphorase, 0.1 mg; triton X-
100, 2 lL; and nitroblue tetrazolium, 1 mg. Reagent (50 lL) was
J. Defaux et al. / Bioorg. Med. Chem. 19 (2011) 1702–1707 1707added to each well and mixed, and plates were incubated for
10–15 min at 37 C. Absorbances were read at 550 nm using a
Dynatech Laboratories MRX microplate reader and % inhibition of
growth was calculated by comparison with control values. IC50 val-
ues were determined using linear regression analysis (Microsoft
Excel).
4.4. Cytotoxic activity against rat skeletal myoblast L6 cells
Cytotoxicity against mammalian cells was assessed using
microtitre plates following a described procedure.41 Brieﬂy, L6 cells
(a rat skeletal muscle line) were seeded at 1  104 ml1 in 200 lL
of growth medium containing different compound concentrations.
The plates were incubated for 6 days at 37 C and 20 lL Alamar
Blue (Biosource UK Ltd) was then added to each well. After a
further 8 h incubation, the ﬂuorescence was determined using a
Gemini ﬂuorescent plate reader (Molecular Devices).
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